Role of Blood Transfusion in India Thalassemia Market
Blood transfusion remains a critical treatment in the India Thalassemia Market, helping manage severe anemia and reduce complications in thalassemia patients. Regular transfusions are essential for long-term care.
The market was valued at USD 310 million in 2023 and is projected to reach USD 485 million by 2032, growing at a CAGR of 5.6%. Hospitals and specialized clinics are primary providers of transfusion services.
Advances in blood screening, storage, and transfusion protocols have improved safety and efficacy. Awareness initiatives encourage timely diagnosis and regular follow-ups.
The India Thalassemia Market segment emphasizes blood transfusions as a significant driver in both therapeutic management and overall market growth.